Epiphany Biosciences Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 3

Epiphany Biosciences General Information

Description

Developer of small molecule therapeutics intended to treat diseases of herpes virus origin. The company has developed antiviral therapeutics to prevent the spread of the varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis C virus (HCV).

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • One California Street
  • Suite 2800
  • San Francisco, CA 94111
  • United States
+1 (415) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Epiphany Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 29-Sep-2021 000.00 Completed Startup
1. Early Stage VC (Series A) 14-Mar-2007 000.00 000.00 0000 Completed Startup
To view Epiphany Biosciences’s complete valuation and funding history, request access »

Epiphany Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00 00.000
To view Epiphany Biosciences’s complete cap table history, request access »

Epiphany Biosciences Patents

Epiphany Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160346287-A1 Method of treating viral infections Abandoned 21-Sep-2012 0000000000
US-20150050241-A1 Method of treating viral infections Abandoned 21-Sep-2012 0000000000 0
JP-2013503197-A Novel nucleoside phosphonates and their analogs Pending 27-Aug-2009 00000000000 0
AU-2010292500-A1 Novel nucleoside phosphonates and analogs Abandoned 27-Aug-2009 00000000000
CA-2772261-A1 Novel nucleoside phosphonates and analogs Abandoned 27-Aug-2009 C07F9/65616
To view Epiphany Biosciences’s complete patent history, request access »

Epiphany Biosciences Executive Team (4)

Name Title Board Seat Contact Info
Fred Volinsky MD Chief Executive Officer, Co-Founder and Chairman
Michael Houghton Chief Scientific Officer
Steve Blank Co-Founder
You’re viewing 3 of 4 executive team members. Get the full list »

Epiphany Biosciences Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CDIB BioScience Venture Management Venture Capital Minority 000 0000 000000 0
Global Trust Ventures PE/Buyout Minority 000 0000 000000 0
Windsor Bay Capital Other Minority 000 0000 000000 0
To view Epiphany Biosciences’s complete investors history, request access »